SITC 2023 Highlights: Biocytogen’s Novel Assets and Products

The Biocytogen team concluded a successful SITC 2023 event, after presenting 9 drug asset posters, 7 genetically engineered mouse model posters, and connecting with current and prospective clients at booth 223. Summarized below are the highlights presented from each product/research area:

Bispecific ADC Assets

Advantages of BsADCs

Biocytogen’s R&D team developed a series of fully human bispecific antibodies (bsAbs) with multi-species cross reactivity from our proprietary fully human common light chain antibody RenLite^® mice. These bsAbs were subsequently assembled into bispecific ADCs (bsADCs), which have distinct advantages over monoclonal ADCs, including enhanced internalization, improving payload enrichment in heterogeneous tumors and achieving broader killing of tumors with varying levels of dual-target expression.

Introduction of a proprietary payload

In addition to prior work evaluating vcMMAE-conjugated bsADCs, SITC 2023 posters disclosed the most recent data of Biocytogen’s proprietary novel DNA topoisomerase I inhibitor payload and cleavable linker system (BLD1102). Preclinical research indicated that BLD1102 has excellent hydrophilicity, good in vivo and in vitro stability, efficient intratumoral payload release, broad tumor killing capacity, and powerful bystander killing. Many BLD1102-conjugated bsADCs exhibited strong tumor killing effects in a variety of solid tumor models, including Dxd and MMAE-resistant models. All of the above results indicate that the BLD1102 bsADCs could be next-generation ADC therapeutics that provide new treatment options for many types of solid tumors.

BsADC Asset Posters: 

Preclinical evaluation of fully human bispecific antibody-drug candidates targeting HER3 and the juxtamembrane region of MUC1

BSA01, a bispecific antibody-drug conjugate targeting EGFR and membrane-bound MUC1-C, exhibits anti-tumor efficacy in vivo

BCG022: A HER3×MET bispecific antibody-drug conjugate (BsADC) targeting key mechanisms of bypass resistance in multiple tumor types

A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts

Fully human TCR-mimic antibody assets

Novel antibodies for intracellular targets

Using our novel RenMice-based TCR-mimic platform, we screened out KRAS G12V7-16 fully human antibodies complexed with different HLA types. KRAS G12V/HLA-A03 antibodies have excellent specificity and the bispecific T cell engager assembled with CD3 nanobodies showed good in vitro killing activity. In another project, we screened out highly specific NY-ESO-1/HLA-A02 fully human antibodies which demonstrated good in vitro and in vivo anti-tumor activity when assembled into TCRm-T cell therapy.

Fully Human TCRmimic Asset Posters:

Identification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMabTM mice

Preclinical application of a fully human TCR-mimic antibody developed to target NY-ESO-1/HLA-A02

Monoclonal antibody assets

Our TIGIT blocking fully human IgG1 antibodies generated from RenMab mice have unique binding epitopes, good physiochemical properties and superior in vivo efficacy when compared to a benchmark antibody.

Fully human monoclonal antibody asset poster:

Fc-competent fully human anti-TIGIT blocking monoclonal antibodies demonstrated potent anti-tumor efficacy in preclinical models

Off-the-Shelf Mouse Models – Humanized Mice

Several exciting new animal models were introduced at SITC that can be used for testing novel immunotherapies: 

Off-the-Shelf Mouse Models – Immunodeficient Target Humanized Mice

For more information, contact us:

Antibody assets: [email protected]

BioMice models: [email protected]

Event Date: Nov 1-5, 2023 | Event Location: San Diego, CA